Clinical Trial Update: Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT) [Phase 3]

View source ↗

Summary

Phase 3 Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT) has completed; it evaluated naproxen and celecoxib for preventing Alzheimer's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Celecoxib (Celecoxib)
• Naproxen (Naproxen)

Snippet

Sponsor: Seattle Institute for Biomedical and Clinical Research | Conditions: Alzheimer Disease | Phase 3 | Status: COMPLETED